# Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

> **NCT05498792** · EARLY_PHASE1 · RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 12 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Melanoma

## Interventions

- **DRUG:** CBL0137
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05498792
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-30
- **Primary completion:** 2026-03-04
- **Final completion:** 2026-09-02
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05498792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05498792, "Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05498792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*